Previous close | 188.91 |
Open | 188.19 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 186.89 - 192.87 |
52-week range | 160.60 - 234.73 |
Volume | |
Avg. volume | 1,201 |
Market cap | 27.938B |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | 0.76 |
EPS (TTM) | 2.54 |
Earnings date | 28 Aug 2024 - 02 Sept 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Veeva Systems (NYSE: VEEV) today revealed that targeted pre-launch scientific outreach maximizes medical affairs teams' impact on treatment adoption in the latest Veeva Pulse Field Trends Report. The analysis shows biopharmas investing in pre-launch scientific activities and prioritizing congresses gain 40% faster treatment adoption than those that invested less. Early-career experts are also more open to digital engagement and four times more likely to start patients on a new treatment.
Veeva Systems (VEEV) closed the most recent trading day at $184.25, moving -1.32% from the previous trading session.
Veeva Systems' (VEEV) Vault EDC is likely to aid the CRO in delivering a better experience to patients, research sites and sponsors.